MicroRNAs (miRNAs) are found ubiquitously in biological cells and play a pivotal role in regulating the expression of numerous target genes. Therapies centered around miRNAs are emerging as a promising strategy for disease treatment, aiming to intervene in disease progression by modulating abnormal miRNA expressions. The accurate prediction of miRNA-drug resistance (MDR) is crucial for the success of miRNA therapies. Computational models based on deep learning have demonstrated exceptional performance in predicting potential MDRs. However, their effectiveness can be compromised by errors in the data acquisition process, leading to inaccurate node representations. To address this challenge, we introduce the GAM-MDR model, which combines the graph autoencoder (GAE) with random path masking techniques to precisely predict potential MDRs. The reliability and effectiveness of the GAM-MDR model are mainly reflected in two aspects. Firstly, it efficiently extracts the representations of miRNA and drug nodes in the miRNA-drug network. Secondly, our designed random path masking strategy efficiently reconstructs critical paths in the network, thereby reducing the adverse impact of noisy data. To our knowledge, this is the first time that a random path masking strategy has been integrated into a GAE to infer MDRs. Our method was subjected to multiple validations on public datasets and yielded promising results. We are optimistic that our model could offer valuable insights for miRNA therapeutic strategies and deepen the understanding of the regulatory mechanisms of miRNAs. Our data and code are publicly available at GitHub:https://github.com/ZZCrazy00/GAM-MDR.
Keyphrases
- multidrug resistant
- deep learning
- randomized controlled trial
- systematic review
- electronic health record
- working memory
- big data
- adverse drug
- lymph node
- neural network
- transcription factor
- gene expression
- poor prognosis
- signaling pathway
- genome wide
- high resolution
- convolutional neural network
- radiation therapy
- climate change
- binding protein
- cell proliferation
- long non coding rna
- patient safety
- single molecule
- machine learning
- risk assessment
- single cell
- early stage
- data analysis
- neoadjuvant chemotherapy
- mass spectrometry
- quality improvement
- combination therapy
- human health